

Neuro-symbolic XAI for Computational Drug Repurposing

Martin Drancé^a, Marina Boudin, Fleur Mougin^b and Gayo Diallo^c

Inserm U1219, Bordeaux Population Health Research Center, Team ERIAS, University of Bordeaux, France

Keywords: Artificial Intelligence, XAI, Drug Repurposing, Knowledge Graph, Bioinformatics.

Abstract: Today in the health domain, the challenge is to build a more transparent artificial intelligence, less affected by the opacity intrinsic to the mathematical concepts it uses. Among the fields which use AI techniques, is drug development, and more specifically drug repurposing. DR involves finding a new indication for an existing drug. The hypotheses generated by DR techniques must be validated. Therefore, the mechanism of generation must be understood. In this paper, we describe the use of a state-of-the-art neuro-symbolic algorithm in order to explain the process of link prediction in a knowledge graph-based computational drug repurposing. Link prediction consists of generating hypotheses about the relationships between a known molecule and a given target. More specifically, the implemented approach allows to understand how the organization of data in a knowledge graph changes the quality of predictions.

1 INTRODUCTION

Today, it costs about 1.5 billion dollars and about fifteen years of research to develop a new drug (DiMasi et al., 2016). These constraints are limiting factors that do not encourage the pharmaceutical industry, which is primarily concerned with cost-effectiveness. In particular, they do not invest in the development of new drugs for so-called rare diseases. In this context, over the last decade, drug repurposing (DR), which consists of searching for a new indication for an existing drug (link between an existing molecule and a given indication), has been attracting growing interest. Advances in Artificial Intelligence (AI) methods have made it possible to develop AI-based computational DR with very encouraging results (Ashburn and Thor, 2004)(Stokes et al., 2020).

However, the use of “black-box” models, which are completely opaque to the understanding of their users (biomedical experts, clinicians, etc.), is currently one of the main obstacles to the use of AI in the health field. In this field indeed, AI should not be seen as a decision maker per-se, but rather as a transparent support to the users’ decision process. Recently, new explainable AI (XAI) models, referred to as neuro-symbolic models, have been developed. These latter AI models are transparent by nature, i.e. users can

Table 1: Type and number of entities (nodes) in the OREGANO KG.

Type	Number
ATC Code	1,005
Drug	42,856
Gene	35,602
Effect	153
Target	254,289
Disease	8,997
Pathway	297
Activity	74
Phenotype	11,202
Indication	2,154
Side Effect	5,556

find and understand the mechanisms leading to a prediction without having to modify, simulate or process any information about the model’s operation itself. Neuro-symbolic models combine symbolic and statistical learning (Das et al., 2018). This combination allows for robust predictions made by a neural network, supported by the transparency provided by the use of logical rules, understandable by humans. Among the many advantages of using these neuro-symbolic models, a major benefit is the possibility of interaction between the model and users during the learning process. Indeed, models that provide an explanation of how they work can more easily be adjusted in the event that some bias is detected.

^a <https://orcid.org/0000-0001-6365-531X>

^b <https://orcid.org/0000-0002-7436-3010>

^c <https://orcid.org/0000-0002-9799-9484>

These models are now being applied to knowledge graphs (KGs) in the context of DR. According to (Paulheim, 2017), a KG has the following characteristics: (i) it describes real-world entities and their interactions within a graph, (ii) it defines classes and relationships between these entities in the form of a schema, (iii) it allows entities to be arbitrarily linked together, and (iv) it can aggregate information from different domains. These data structures are well suited for describing biomedical information, as they are usually derived from multiple databases and KGs are perfect for maintaining the semantic relationship between entities. Recently, as proved by (Himmelstein et al., 2017) and (Zhang et al., 2021), KG-based DR has demonstrated interesting results through the use of AI models and algorithms to predict new links between existing entities in KGs. Unfortunately, the lack of transparency of the models prevents the results from being used more widely by experts in the field of DR, including biochemists and clinicians.

The current study is part of the OREGANO project which aims to provide an end-to-end framework for KG-based computational DR (Boudin, 2020). Specifically, we describe the exploitation of a state-of-the-art neuro-symbolic model and algorithm in the OREGANO workflow to explain the results of the link prediction process. Link prediction here consists of generating hypotheses about the relationships between a known molecule and a given target. To do this, we used PoLo (*Policy-guided walks with Logical rules*) (Liu et al., 2021), a neuro-symbolic model achieving state-of-the-art results in KG link prediction. It has already been used in the context of the Hetionet KG (Himmelstein et al., 2017) to repurpose drugs. In our work, we particularly investigated how the structure of data in a KG changes the quality of predictions.

2 MATERIALS AND METHODS

2.1 Data

The data that are used to develop the OREGANO KG have been previously collected in the context of the work described in (Boudin, 2020). They come from various free and/or open source knowledge bases and Linked Open Data. They have been then curated and integrated into the OREGANO KG depicted in Figure 1. Currently, this graph has a total of 362,186 nodes of 11 different types and 802,949 relations of 19 different types. The detailed number of nodes per data type can be found in Table 1 while the number of relations (edges) is provided in Table 2.

Table 2: Type and number of relations (edges) in the OREGANO KG.

Type	Number
associated_to	250,000
causes_condition	8,584
decreases_activity	2,446
decreases_effect	102
decreases_efficacy	106,558
has_activity	5,565
has_code	3,150
has_effect	11,251
has_indication	8,307
has_phenotype	76,177
has_side_effect	129,330
has_target	50,132
increases_activity	6,636
increases_effect	10,041
increases_efficacy	34,071
is_affecting	5,341
is_substance_that_treats	60,889
participates_in	24,919

2.2 Link Prediction

PoLo (Liu et al., 2021) is an algorithm that was proposed in March 2021 to perform link prediction from a KG. It is one of the only fully neuro-symbolic algorithms that relies as much on mathematical methods as on the use of logical rules from the information contained in the KG on which it operates. Its operation is inspired by MINERVA (Das et al., 2018), both of which are based on the use of reinforcement learning in order to optimize the movements of an agent in the graph and thus make link prediction. From an initial entity (here, a drug to be repurposed), an agent moves in the graph from node to node. The decision of which node to choose for the next move is determined by a policy set by a long short-term memory (Hochreiter and Schmidhuber, 1997). The transitions between the nodes accumulate and form a path that represents a chain of reasoning. These iterations are repeated a finite number of times, until the agent obtains a reward, based on the path taken and the associated prediction. This learning task is modeled as a Markov decision process.

2.3 Logical Rules

PoLo uses meta-paths, in the form of Horn rules, to evaluate the gain provided to the agent according to its predictions. In order to work, PoLo needs a set of meta-paths that are considered reliable and that describe possible paths between the entities to be re-




Figure 1: Schema of the OREGANO KG.

purposed, in this case between a drug and a disease. These meta-paths must be “scored” according to their reliability, a very reliable path having a score close to 1 and a very unreliable path a score close to 0. An example of a meta-path is described as follows:

Aspirin $\xrightarrow{\text{treats}}$ *Headache* $\xrightarrow{\text{caused_by}}$ *Dehydration*

and becomes :

Drug $\xrightarrow{\text{treats}}$ *Symptom* $\xrightarrow{\text{caused_by}}$ *Cause*

As mentioned in (Liu et al., 2021), AnyBURL (*Any-time Bottom-Up Rule Learning algorithm*) (Meilicke et al., 2019) was applied to the OREGANO KG to identify a set of rules intrinsic to the data. These rules were transformed into meta-paths that were used by PoLo during its learning phase. Based on these meta-paths, PoLo evaluates the reward to be given to the agent responsible for the link prediction.

2.4 Discovery Patterns

In addition to PoLo’s explainable logic rules, discovery patterns have been used as proposed in (Himmelsstein et al., 2017) and (Zhang et al., 2021). Discovery patterns based on the exploration of semantic links between data allow the discovery of mechanistic links between entities in a KG, but also to strengthen the explanation of the prediction provided by the AI algorithm. To provide a visual exploration, we relied on Neo4j¹, together with its query language Cypher.

¹<https://neo4j.com/>

It is a system for building and manipulating data in the form of a graph-oriented database (GDB). These GDBs have the advantage of preserving the structure of the KG, by storing the information contained in the nodes but also in the edges. Thus, the modeling of complex data and queries are facilitated. From the OREGANO project data, a GDB has been built on Neo4j. The purpose of this GDB is to bring an additional explanation and visualization, in order to invalidate or validate the predictions made by PoLo. The advantage of this method is that it offers the possibility to build precise queries, allowing access to information or links that had not been spotted by AnyBURL or PoLo, but that do exist in the data.

2.5 Impact of the Data in the KG

As with any machine learning task, it is important to consider the format of the data. Much of the current research attempts to improve the results of link prediction by improving the performance of the algorithms. However, in the areas of AI that have grown in recent years, there has been an evolution of algorithms along with data processing methods. These methods ensure optimal learning, for example by modifying or augmenting the data. For KGs, as far as we know, little or no work has been done to determine the best way to structure the data in KG and its possible impact on the predictions. A first approach studied here concerns the importance of the ratio between the entities of the KG. Let r be the relationship of interest linking two types

of entities $T1$ and $T2$, what is the optimal number of objects of types $T1$ and $T2$ in the graph to achieve a good prediction? To answer this question in the context of DR, several types of link prediction have been tested. First, AnyBURL and PoLo were used to predict the following types of links:

- *associated_to* between a protein and a gene;
- *causes_condition* between a gene and a disease;
- *has_phenotype* between a disease and a phenotype;
- *has_target* between a drug and a protein;
- *is_affecting* between a drug and a gene;
- *is_substance_that_treats* between a drug and a disease;
- *participates_in* between a gene and a pathway.

In a second approach, the relation between the amount of training data and the quality of the prediction was tested. For this purpose, the link prediction task is re-run focusing exclusively on the links *has_target* and *is_substance_that_treats*, but changing the number of triples of these types. For each type of relation, the first experiments have been launched with 5000 triples, then 5000 triples are added per additional experiment, until all the triples are reached.

3 RESULTS

Table 3 shows the Mean Reciprocal Rank (MRR) score for each PoLo link prediction based on the different relation types. These results show that the quality of predictions cannot be solely related to the quality of the extracted rules or their number. Indeed, the best predictions are reached for the *is_substance_that_treats* relation for which 630 rules are available with the best confidence index equal to 0.70. However, for the *is_affecting* relation, the MRR is close to 0 while many rules are also available and have a satisfactory confidence index. In contrast, the predictions for the relation *causes_condition* are ranked third in terms of MRR, with only 112 Horn rules available and a confidence index three times lower than that of *is_affecting*. Predictions involving *participates_in* achieve an MRR of 0.3 based on only 68 rules.

Regarding the impact of the amount of training data, the results are presented in Figure 2. These results show that, for both relations, increasing the amount of training data has rather a negative impact on the quality of predictions. Furthermore, we can clearly see the correlation between the MRR and the number of times a rule given by AnyBURL produces the correct result.

As a final result for the DR problem, best results were found when predicting the relation *is_substance_that_treats* and can be found in Table 4. These results, which are slightly better than with Heterionet, are only partial results, the other (major) part coming from the explanations provided by PoLo for each of the predictions made. From this generated file, the following results emerged:

- 682 drugs were identified as candidates for being repurposed;
- these candidates impact a total of 447 diseases;
- out of 630 Horn rules provided by AnyBURL to PoLo, only 10 of them were effectively used for predictions;
- on these 10 rules, the most frequent one has been used 600 000 times, the second only 21 000 times.

4 DISCUSSION

The use of PoLo to repurpose drugs through link prediction has produced a significant amount of results. These results reached an accuracy not previously achieved from the OREGANO KG using other methods such as TransE (Bordes et al., 2013). Moreover, the use of a neuro-symbolic model offers reliable explanations for the origin of each prediction. These results need to be analyzed by DR experts in order to get the best out of them. It is with this in mind that these results are currently being further investigated by the clinical genetics unit of the Bordeaux University Hospital. The aim of this collaboration is to give access to the results to clinicians who will be able to evaluate and select those they consider most interesting to explore in their research. The possible explanation for each repurposing will come from logical rules used by PoLo but also from the post-hoc mechanistic explanation provided by the visualization capability of the Neo4j graph database.


Regarding the fact that providing more training data does not help to obtain better predictions, two important points should be highlighted:

- The quality and number of rules produced by AnyBURL are not systematically correlated with the quality of a prediction;
- The increase in the number of triples in the training data does not necessarily mean an improvement in performance.

This last point is particularly interesting since it is counter-intuitive. We observe that, in both cases, the MRR drops when the number of rules producing a correct prediction decreases, which is normal if we consider that the PoLo agent's gain is directly related to

Table 3: MRR (Mean Reciprocal Rank) produced by PoLo for each type of relation, based on the best quality and number of rules extracted by AnyBURL.

Relation	Number	Best Score	MRR
associated_to	21	0.43	0.0003
causes_condition	112	0.14	0.15
has_phenotype	96	0.11	0.07
has_target	489	0.163	0.07
is_affecting	399	0.42	0.004
is_substance_that_treats	630	0.70	0.49
participates_in	68	0.92	0.3

Figure 2: Impact of the number of relations in the training data for *is_substance_that_treats* on the left and *has_target* on the right.

the path taken for the prediction. These results therefore suggest that a surplus of training data makes the use of the rules proposed by AnyBURL rarer, leading to less frequent rewards and thus to a decrease in performance of PoLo predictions. Another explanation for this decrease in performance could be how more training data brings more noise to the system. PoLo uses training triples to determine what are the diseases for which drugs can be repurposed. The more training data, the more different diseases can be proposed as a result. Based on this observation, a useful step that could be added would be to filter the training data to keep only those that contain diseases of interest.

The disparity of the metrics according to the type of relation chosen demonstrates the importance of the structure of the data in the prediction task. Today, AI research in the field of drug repositioning focuses mainly on improving prediction algorithms, without really paying attention to the data and its quality. These new models are systematically tested on the same evaluation datasets, without ever reconsidering their structure. However, it is necessary to understand how the organization of the data within a KG changes the quality of the predictions, not least because biomedical data in general are different from the “test” datasets typically used in the literature. In addition

to these considerations around data, it is important to remember that the goal of more transparent AI is to be trusted by clinicians and other healthcare experts. With this in mind, algorithms should be proposed that allow for greater interaction with clinicians, in order to offer greater flexibility in the choice of how they operate, as here with the logical rules to be followed. Currently, the set of “good” logical rules to follow is given to PoLo using AnyBURL. AnyBURL is a powerful tool for extracting the main logical rules and meta-paths that exist in a KG, but these rules are ranked based on their ability to describe the data, not on their relevance from a medical perspective. Since PoLo is trained using these rules in the reinforcement learning process, it will be important to filter these rules to keep only those that are medically plausible. Another way to do this is to have the clinicians construct the rules themselves, based on their *a priori* knowledge. The fact that PoLo only used 10 of the 630 proposed rules and only one of them most of the time (600 000 times) shows that these rules are not efficient in repurposing drugs. This is also a problem when considering the use of reinforcement learning based on these rules, as the agent should be rewarded when it uses different medically valid rules and not when it uses only the most common one among the data.

Table 4: Comparison of the metrics obtained for drug repositioning through the *is_substance_that_treats* relation on the OREGANO KG with the results obtained on Hetionet.

Data	MRR	Hits@1	Hits@3	Hits@10
OREGANO	0.4980	0.3898	0.5551	0.7300
HETIONET	0.4300	0.3370	0.4700	0.6410

5 CONCLUSION

In this paper, we have described a neuro-symbolic XAI solution applied to the DR task using a KG. The study has been implemented and evaluated in the context of the OREGANO project using a state-of-the-art algorithm which enables the explainability. Results equivalent to those of the state of the art were obtained, as well as several ways to provide an explanation for each prediction, i.e. intrinsic to the model's operation, but also post-hoc in a mechanistic way using features of a graph oriented database. The challenges surrounding this work are numerous. First, it is important to better understand how the organization of data in a KG affects the prediction task. This will be particularly important for the application of these methods to DR for rare diseases, where data is by definition less abundant. Also, more flexible methods must be thought of, allowing biochemists and other clinicians to easily participate in the learning process, bringing their knowledge to the sum of data available for DR.

REFERENCES

- Ashburn, T. and Thor, K. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. *Nature reviews Drug discovery*, 3:673–83.
- Bordes, A., Usunier, N., García-Durán, A., Weston, J., and Yakhnenko, O. (2013). Translating embeddings for modeling multi-relational data. In *Advances in Neural Information Processing Systems 26*.
- Boudin, M. (2020). Computational approaches for drug repositioning: Towards a holistic perspective based on knowledge graphs. *Proceedings of the 29th ACM International Conference on Information & Knowledge Management*, page 3225–3228.
- Das, R., Dhuliawala, S., Zaheer, M., Vilnis, L., Durugkar, I., Krishnamurthy, A., Smola, A., and McCallum, A. (2018). Go for a walk and arrive at the answer: Reasoning over paths in knowledge bases using reinforcement learning. In *International Conference on Learning Representations*.
- DiMasi, J. A., Grabowski, H. G., and Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of r&d costs. *Journal of Health Economics*, 47:20–33.
- Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., and Baranzini, S. E. (2017). Systematic integration of biomedical knowledge prioritizes drugs for repurposing. *eLife*, 6:e26726.
- Hochreiter, S. and Schmidhuber, J. (1997). Long Short-Term Memory. *Neural Computation*, 9(8):1735–1780.
- Liu, Y., Hildebrandt, M., Joblin, M., Ringsquandl, M., Raisouni, R., and Tresp, V. (2021). Neural multi-hop reasoning with logical rules on biomedical knowledge graphs. In Verborgh, R., Hose, K., Paulheim, H., Champin, P.-A., Maleshkova, M., Corcho, O., Ristoski, P., and Alam, M., editors, *The Semantic Web*, pages 375–391, Cham. Springer International Publishing.
- Meilicke, C., Chekol, M. W., Ruffinelli, D., and Stuckenschmidt, H. (2019). Anytime bottom-up rule learning for knowledge graph completion. In *IJCAI*.
- Paulheim, H. (2017). Knowledge graph refinement: A survey of approaches and evaluation methods. *Semantic Web*, 8:489–508.
- Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A. H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., and Collins, J. J. (2020). A deep learning approach to antibiotic discovery. *Cell*, 180(4):688–702.e13.
- Zhang, R., Hristovski, D., Schutte, D., Kastrin, A., Fiszman, M., and Kilicoglu, H. (2021). Drug repurposing for covid-19 via knowledge graph completion. *Journal of Biomedical Informatics*, 115:103696.